Alaunos Therapeutics (TCRT) investor relations material

Executive summary

• Net loss of $1.0 million for Q1 2026, with an accumulated deficit of $925.6 million as of March 31, 2026, and no product revenue generated to date.

• Focus remains on advancing a preclinical oral small molecule program for obesity and metabolic disorders, with recent positive preclinical data for lead compound ALN1003.

• Company faces substantial doubt about its ability to continue as a going concern due to limited cash resources and lack of committed capital.

Financial highlights

• Revenue for Q1 2026 was $0, compared to $2,000 in Q1 2025, reflecting the end of royalty income.

• Research and development expenses increased 23% year-over-year to $427,000, driven by higher stock-based compensation, salaries, and consulting fees.

• General and administrative expenses decreased 22% year-over-year to $585,000, mainly due to lower salaries, insurance, and other costs.

• Net loss attributable to common stockholders was $1.16 million, including $149,000 in cumulative preferred dividends.

• Cash and cash equivalents were $354,000 at quarter-end, with a monthly cash burn rate of $340,000.

Outlook and guidance

• Cash resources are expected to fund operations only into Q2 2026; additional capital is required to continue development activities.

• Plans to advance ALN1003 into further preclinical and IND-enabling studies are contingent on securing new funding.

• Strategic financing, collaborations, or other transactions are being actively explored.